Neurodegenerative Diseases Drugs Market Size, Share and Industry Analysis By Drug Class (Immunomodulator, Interferons, Decarboxylase Inhibitors, Dopamine Agonists, Others), By Disease Indication (Multiple Sclerosis, Parkinsons Disease, Alzheimers Disease, Spinal Muscular Atrophy (SMA), Others), By Route of Administration (Oral, Injection, Transdermal, Others), By End User and Regional Forecast 2020-2029 (Includes COVID-19 Business Impact)

                                          
We have updated Neurodegenerative Diseases Drugs Market with respect to COVID-19 Business Impact.
Inquire before buying

This report focuses on the Neurodegenerative Diseases Drugs market and value at the global level, regional level, and company level. From a global perspective, this report represents the overall Neurodegenerative Diseases Drugs market size by analyzing historical data and future prospects. Regionally, this report focuses on several key regions: North America, Europe, Japan, China, Southeast Asia, India, Latin America, and South America.

Global Neurodegenerative Diseases Drugs Market: Segment Analysis


The research report includes specific segments by region (country), by Company, by Type, and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2019 to 2029. An in-depth analysis of the segments assists in identifying the different factors that will aid market growth.

Global Neurodegenerative Diseases Drugs Market: Regional Analysis

The research report includes a detailed study of regions of North America, Europe, Japan, China, Southeast Asia, India, Latin America, and South America. The report has been curated after observing and studying various factors that determine regional growth such as the economic, environmental, social, technological, and political status of the particular region. Researchers have studied the data of revenue, sales, and manufacturers of each mentioned region. This section analyses region-wise revenue and volume for the forecast period of 2019 to 2029.

Global Neurodegenerative Diseases Drugs Market: Competitive Landscape

This section of the report identifies various key manufacturers of the market. It helps the reader understand the strategies and collaborations that players are focusing on combat competition in the market. The comprehensive report provides a significant microscopic look at the market. The reader can identify the footprints of the manufacturers by knowing about the global revenue of manufacturers, the global price of manufacturers, and sales by manufacturers during the forecast period of 2019 to 2029.
List of Companies Profiled

 	
Biogen
 	
Pfizer, Inc.
 	
Hoffmann-La Roche Ltd
 	
Merck & Co., Inc.
 	
Novartis AG
 	
Sanofi
 	
Teva Pharmaceutical Industries Ltd.
 	
Orion Pharma
 	
UCB S.A
 	
ACADIA Pharmaceuticals Inc.
 	
Lundbeck A/S
 	
Mitsubishi Tanabe Pharma Corporation
 	
Other players

Report Coverage

Neurodegenerative diseases refer to the neurological diseases that mainly affect the neurons of human brains. Neurodegenerative disease imposes not only a substantial burden on global healthcare cost but also on the mental and physical health of the population. Alzheimers Disease, Parkinsons Disease, Multiple sclerosis, and amyotrophic

lateral sclerosis are the major neurodegenerative diseases. According to the European Multiple Sclerosis Platform (EMSP), approximately 762,760 people in Europe were estimated to have multiple sclerosis in 2015.
According to the European Parkinsons Disease Association, more than 1.2 million people in Europe are living with

Parkinsons Disease, which is expected to double by 2030. Neurodegenerative diseases advance with age; the number of neurodegenerative diseases cases is expected to increase dramatically as the life span of people in many countries continues to increase. Molecular epidemiology and molecular techniques such as genomics, proteomics, and others have provided better insights into the diseases resulting in increased research on novel therapy and presence of potential pipeline drugs candidates. Government research grants, strategic research collaborations, high pricing of the drugs, and active government support have resulted in a huge surge in demand for neurodegenerative diseases drugs.

The report provides qualitative and quantitative insights on the neurodegenerative diseases drugs industry and detailed analysis of neurodegenerative diseases drugs market size and growth rate for all possible segments in the market. The market is segmented by drug class, by disease indication, by route of administration, by distribution channel, and by region. On the basis of the drug class, the global market is segmented into immunomodulator, interferons, decarboxylase inhibitors, dopamine agonists, and others.

Based on disease indication, the global neurodegenerative diseases drugs market is categorized into multiple sclerosis, Parkinsons disease, Alzheimers disease, spinal muscular atrophy, and others. In terms of the route of administration, the market is divided into oral, injection and transdermal. Various distribution channels covered under the report are hospital pharmacy, retail pharmacy, and online pharmacy. Geographically, the market is segmented into four major regions, which are North America, Europe, Asia Pacific, Latin America, the Middle East & Africa. The regions are further categorized into countries.

Along with this, the report provides an elaborative analysis of the market dynamics and competitive landscape. The report offers key insights on the prevalence of neurodegenerative diseases for key countries, pipeline analysis, patent snapshot, regulatory scenario for key countries, new product launch, recent industry developments such as mergers & acquisitions, the regulatory scenario in key countries, and key industry trends.

SEGMENTATION

By Drug Class

 	
Immunomodulator
 	
Interferons
 	
Decarboxylase Inhibitors
 	
Dopamine Agonists
 	
Others

By Disease Indication

 	
Multiple Sclerosis
 	
Parkinsons Disease
 	
Alzheimer"s Disease
 	
Spinal Muscular Atrophy (SMA)
 	
Others

By Route of Administration

 	
Oral
 	
Injection
 	
Transdermal

By End User

 	
Hospital Pharmacy
 	
Retail Pharmacy
 	
Online Pharmacy

By Geography

 	
North America (USA and Canada)
 	
Europe (UK, Germany, France, Italy, Spain, Scandinavia and Rest of Europe)
 	
Asia Pacific (Japan, China, India, Australia, Southeast Asia and Rest of Asia Pacific)
 	
Latin America (Brazil, Mexico and Rest of Latin America)
 	
Middle East & Africa (South Africa, GCC and Rest of the Middle East & Africa)

Key Industry Developments

In October 2020, Accord Healthcare S.L.U. received marketing authorisation valid throughout the European Union for Fampridine Accord which is a medicine used to improve walking ability in adults with multiple sclerosis (MS) who have a walking disability. MS is a disease in which the immune system (the body’s defences) attacks and damages the covering around the nerves and the nerves themselves in the brain and spinal cord. Fampridine Accord is a ‘generic medicine’. This means that Fampridine Accord contains the same active substance and works in the same way as a ‘reference medicine’ already authorised in the EU called Fampyra. Fampridine Accord contains the active substance fampridine. Fampridine is a board-spectrum lipophillic potassium channel blocker and binds favourably to the open state than closed state of the potassium channel in the CNS. Its pharmacological target are the potassium channels exposed in MS patients and does not prolong the QTc interval.

Fampridine Accord has been shown to have comparable quality and to be bioequivalent to Fampyra. Therefore, the Agency’s view was that, as for Fampyra, the benefits of Fampridine Accord outweigh the identified risks and it can be authorised for use in the EU.

In March 2019, Novartis AG announced the FDA approval for Mayzent, an immunomodulator for the treatment of relapsing forms of multiple sclerosis (RMS).

In January 2018, Eisai Co., Ltd. collaborated with Biogen for the co-promotion of TECFIDERA, TYSABRI, and AVONEX in Japan.

In February 2017, Apitope, a company for drug discovery and development announced positive results from the Phase IIa clinical study of the companys multiple sclerosis drug candidate named ATX-MS-1467.

In February 2019, Acorda Therapeutics launched INBRIJA, an inhalation powder to treat patient with Parkinsons disease in the U.S.

In June 2017, European Commission (EC) granted marketing approval for SPINRAZA, a drug used for treating spinal muscular atrophy.